ClinicalTrials.gg
CompletedNCT00770497Updated Jul 5, 2010

Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.

A Phase 2 interventional study of Pioglitazone and Pioglitazone and ramipril in Inflammation and Hypertension, sponsored by Takeda. Completed at 13 sites in Germany. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-07-05.

Primary conditionHypertensionRegistry: InflammationReclassifiedWhy we changed it
Registry
Inflammation — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypertension
Why
  1. Inflammation is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Hypertension by Takeda — none open to participants now, none under way, none of them phase 3. Hypertension · Takeda.

Enrollment
21st of 34
172 · median 383
Started
2007
with 7 others
Phase 2
4 of 44
none open now
Registered
13th of 44
by date

Among the 44 studies in Hypertension by Takeda, this one is the 21st largest by enrollment of the 34 interventional ones that give a count, is one of 8 that started in 2007, is one of 4 in phase 2, and was the 13th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 44 studies in Hypertension by Takeda is open now. The open studies under Hypertension, anywhere →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies in Hypertension by Takeda as a file.
02

Study summary

The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on low grade inflammation and vascular function in hypertensive patients.

Read the detailed description

Patients with insulin resistance and an activated inflammation are prone for cardiovascular complications like myocardial infarction or stroke. Pharmacological interventions reducing vascular inflammation are thought to reduce cardiovascular risk in diabetic and in non-diabetic patients.

Intervention with ACE inhibitors like ramipril is an established and widely used treatment for patients with high blood pressure, proven to reduce cardiovascular risk. Treatment of non-diabetic patients with pioglitazone has shown to improve the cardiovascular risk profile in non-diabetic patients beyond its effect on blood glucose levels.

The purpose of this study is to evaluate effects on low grade inflammation and vascular function of pioglitazone in non-diabetic, hypertensive patients with pre treatment with angiotensin converting enzyme inhibitors (that will be replaced by the study medication at time of randomization).

03

Conditions studied

  • Inflammation
  • Hypertension

Browse trials for

Keywords

  • drug effects
  • Hypertension
  • Vascular Resistance
  • Drug Therapy
  • physiopathology, vascular
04

In context

Hypertension Reclassified

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

This study's enrollment of 172 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammation. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has arterial hypertension.
  • Is on stable treatment with an Angiotensin Converting Enzyme inhibitor at least for 12 weeks.
  • Has a high sensitive C-Reactive Protein value greater than 1.0 mg/L and less than 10.0 mg/L.
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Manifests or has newly detected diabetes mellitus type 2 according to World Health Organization criteria.
  • Has Type 1 Diabetes.
  • Has acute infections.
  • Chronic inflammatory diseases which cause elevated CRP-values (e.g. rheumatic diseases, pyelonephritis or osteomyelitis).
  • Use of acetyl salicylic acid and/or Non-steroidal Anti-inflammatory Drugs or Cox-2-inhibitors within the last 4 weeks prior to screening visit, use of Rifampicin within the last 12 weeks prior to screening visit.
  • Uncontrolled hypertension (repeated blood pressure greater than 180/100 mmHg for at least three times within two weeks); persistent hypotension (systolic less than 90 mmHg) or hemodynamic instability.
  • Anamnestic history of to the study drugs or to drugs with similar chemical structures.
  • History of severe or multiple allergies.
  • Treatment with any other drug within 3 months before trial entry.
  • Has a progressive, fatal disease.
  • History of drug or alcohol abuse within the last 5 years.
  • A history of significant cardiovascular ( stage I - IV, hemodynamic relevant aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy), respiratory, gastrointestinal, hepatic ( greater than 2.5 times the normal reference range), renal (creatinine greater than 2.0 mg/dL), or hematological disease, history of macular edema.
  • State after kidney transplantation, hemodynamic relevant renal artery stenosis (bilateral or unilateral in case of single kidney).
  • Blood donation within the last 30 days.
  • Serum potassium greater than 5.5 mmol/L.
  • History of hyperaldosteronism.
  • Treatment with thiazolidinediones within 3 months prior to screening.
  • Acute myocardial infarction, open heart surgery or cerebral events (stroke/) within 30 days prior to screening visit.
  • If statin therapy applicable: Change of medication within the last 12 weeks.
  • History of angioneurotic edema (hereditary or idiopathic as consequence of previous Angiotensin Converting Enzyme inhibitor treatment).
  • Dialysis or hemofiltration.
  • Low Density Lipoprotein apheresis with dextran sulphate.
  • Allergic to toxic agents derived from insects.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    Pioglitazone 15 mg to 30 mg QD

    Drug: Pioglitazone

  • Active comparator
    Pioglitazone 15 mg to 30 mg QD + Ramipril 2.5 mg to 5 mg QD

    Drug: Pioglitazone and ramipril

  • Active comparator
    Ramipril 2.5 mg to 5 mg QD

    Drug: Ramipril

Interventions

  • Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to: Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks.

    Also known as: ACTOS®, AD4833

  • DrugPioglitazone and ramipril

    Drug pages: Pioglitazone · Ramipril

    Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to: Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks.

    Also known as: ACTOS®, AD4833

  • Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to: Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks.

07

What researchers measure

Primary outcomes

  1. Change in the high-sensitivity C-reactive Protein value.

    Time frame: Week: 12.

Secondary outcomes

  1. Change from Baseline in Glucose tolerance as assessed by an oral glucose tolerance test.

    Time frame: Week: 12.

  2. Change from Baseline in Insulin sensitivity according to the Homeostatic Model Assessment - Sensitivity score and Insulin Secretion.

    Time frame: Weeks: 6 and 12.

  3. Change from Baseline in Glycosylated Hemoglobin levels.

    Time frame: Week: 12.

  4. Change from Baseline in C-Peptide levels.

    Time frame: Weeks: 6 and 12.

  5. Change from Baseline in Proinsulin intact levels.

    Time frame: Weeks: 6 and 12.

  6. Change from Baseline in 24 hours Blood Pressure Profile.

    Time frame: Week: 12.

  7. Change from Baseline in high-sensitivity C-reactive Protein levels.

    Time frame: Weeks: 6 and 10.

  8. Change from Baseline in Adiponectin levels.

    Time frame: Weeks: 6 and 12.

  9. Change from Baseline in Monocyte Chemoattractant Protein-1 levels.

    Time frame: Weeks: 6 and 12.

  10. Change from Baseline in Matrix metalloproteinase-9 levels.

    Time frame: Weeks: 6 and 12.

  11. Change from Baseline in P-selectin levels.

    Time frame: Weeks: 6 and 12.

  12. Change from Baseline in Plasminogen Activator Inhibitor-1 levels.

    Time frame: Weeks: 6 and 12.

  13. Change from Baseline in Relaxin levels.

    Time frame: Weeks: 6 and 12.

  14. Change from Baseline in Endothelin 1-21 levels.

    Time frame: Weeks: 6 and 12.

  15. Change from Baseline in Nitrotyrosine levels.

    Time frame: Weeks: 6 and 12.

  16. Change from Baseline in Asymmetric Dimethylarginine levels.

    Time frame: Weeks: 6 and 12.

  17. Change from Baseline in Myeloperoxidase levels.

    Time frame: Weeks: 6 and 12.

  18. Change from Baseline in levels of Oxidative Stress as assessed by Per-Ox-Assay.

    Time frame: Weeks: 6 and 12.

  19. Change from Baseline in Total Cholesterol levels.

    Time frame: Weeks: 6 and 12.

  20. Change from Baseline in Triglycerides levels.

    Time frame: Weeks: 6 and 12.

  21. Change from Baseline in High Density Lipoprotein levels.

    Time frame: Weeks: 6 and 12.

  22. Change from Baseline in Low Density Lipoprotein levels.

    Time frame: Weeks: 6 and 12.

  23. Change from Baseline in Oxidized Low Density Lipoprotein levels.

    Time frame: Weeks: 6 and 12.

  24. Change from Baseline in Soluble Intercellular Adhesion Molecule levels.

    Time frame: Weeks: 6 and 12.

  25. Change from Baseline in Soluble Vascular Cell Adhesion Molecule levels.

    Time frame: Weeks: 6 and 12.

  26. Change from Baseline in Osteoprotegrin levels.

    Time frame: Weeks: 6 and 12.

  27. Change from Baseline in 11-dihydroxy-thromboxan B2 levels.

    Time frame: Weeks: 6 and 12.

  28. Change from Baseline in Placental Growth Factor levels.

    Time frame: Weeks: 6 and 12.

08

Study locations

13 sites
  • Deggingen, Baden-Württemberg, Germany
  • Rottweil, Baden-Württemberg, Germany
  • Spaichingen, Baden-Württemberg, Germany
  • Weilersbach, Bayern, Germany
  • Hannover, Niedersachsen, Germany
  • Essen, Nordrhein-Westfalen, Germany
  • Köln, Nordrhein-Westfalen, Germany
  • Werne, Nordrhein-Westfalen, Germany
  • Mainz, Rheinland-Pfalz, Germany
  • Schauenburg, Rheinland-Pfalz, Germany
  • Dresden, Sachsen, Germany
  • Blankenhain, Thüringen, Germany
  • Berlin, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 10, 2008
Start
Mar 2007
Primary completionActual
May 2008
CompletionActual
May 2008
Last update
Jul 5, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00770497
Lead sponsor
Takeda
First posted
Oct 10, 2008
Start date
Mar 2007
Primary completion
May 2008
Completion
May 2008
Last update
Jul 5, 2010

Study contacts

Medical Adviser Clinical Research
study director · Takeda Pharma Gmbh, Aachen (Germany)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion